Vanda Pharmaceuticals challenged the Food and Drug Administration's refusal to approve its drug Hetlioz, leading to a favorable ruling by the U.S. Court of Appeals for the D.C. Circuit on August 18, 2025.
2 reports, 1 independent
Updated Jul 3
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vanda Pharmaceuticals challenged the Food and Drug Administration's refusal to approve its drug Hetlioz, leading to a favorable ruling by the U.S. Court of Appeals for the D.C. Circuit on August 18, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
-
Vanda Pharmaceuticals (United States)
company in Washington D.C., United States
Related events
Coverage
Newest first; wire copies grouped- PR NewswireIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Vanda Pharmaceutica